LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

Jazz Pharmaceuticals PLC

Closed

SectorHealthcare

108.34 -1.69

Overview

Share price change

24h

Current

Min

107.79

Max

109.6

Key metrics

By Trading Economics

Income

-284M

-93M

Sales

-190M

898M

P/E

Sector Avg

15.2

51.748

EPS

1.68

Profit margin

-10.307

Employees

2,800

EBITDA

-275M

109M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+68.41% upside

Dividends

By Dow Jones

Next Earnings

30 lip 2025

Market Stats

By TradingEconomics

Market Cap

-504M

6.9B

Previous open

110.03

Previous close

108.34

News Sentiment

By Acuity

50%

50%

177 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Jazz Pharmaceuticals PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 lis 2024, 14:45 UTC

Major Market Movers

Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK

31 paź 2024, 15:29 UTC

Major Market Movers

Avadel Pharma Shares Rise on Favorable Ruling for FDA in Lumryz Litigation

Peer Comparison

Price change

Jazz Pharmaceuticals PLC Forecast

Price Target

By TipRanks

68.41% upside

12 Months Forecast

Average 182.73 USD  68.41%

High 230 USD

Low 147 USD

Based on 14 Wall Street analysts offering 12 month price targets forJazz Pharmaceuticals PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

13

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

N/A / 111.22Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

177 / 380 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$